RNA
Atrium Therapeutics, Inc.
$8.40
+0.14
(+1.69%)
Mkt Cap
143.69M
Volume
208,346
52W Range
7.63-16.77
Sector
Healthcare
Beta
0.37
EPS (TTM)
-3.85 USD
P/E Ratio
-3.29
Revenue (TTM)
23.50M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 |
|---|---|
| Revenue | 18.62M |
| Net Income | (76.68M) |
| EPS | -4.48 |
| Free Cash Flow | (42.57M) |
| FCF / Share | -2.49 |
| Operating CF | (41.13M) |
| Total Assets | 278.35M |
| Total Debt | 3.67M |
| Cash & Equiv | 270.00M |
| Book Value | 207.29M |
| Return on Equity | -0.37 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenue | 3.00M | 19.64M | 859,000 | 0 |
| Net Income | (20.19M) | (16.63M) | (48.07M) | (8.29M) |
| EPS | -1.18 | -0.97 | -1.70 | 0.00 |
| Free Cash Flow | (3.96M) | (33.24M) | (20.13M) | N/A |
| FCF / Share | -0.23 | -1.94 | -1.18 | N/A |
| Operating CF | (3.93M) | (31.14M) | (19.25M) | N/A |
| Total Assets | 280.51M | 292.36M | 278.35M | 277.54M |
| Total Debt | 1.68M | 2.68M | 3.67M | 4.28M |
| Cash & Equiv | 72.64M | 267.85M | 270.00M | 270.00M |
| Book Value | 214.58M | 234.10M | 207.29M | 212.85M |
| Return on Equity | -0.09 | -0.07 | -0.23 | -0.04 |
RNA News
Atrium Therapeutics Announces $50 Million Private Placement
Avidity Biosciences (NASDAQ:RNA) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average – Here’s Why